Sina Rashedi, Mariana Pfeferman, Arvind Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth Morrison, Heather Hogan, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr S. Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber, Behnood Bikdeli, Gregory Piazza
This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism ( HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.